Our database has undergone a major update! We expect some minor teething issues, please let us know by using the Report an issue button at the top of every page if you spot anything that doesn't work.

• 1/6 Visit us at the BDNG Annual Conference 2025 in Harrogate!
• 2/6 Recruitment to Taltz has ended
• 3/6 Read more: Changes to conventional cohort eligibility criteria
• 4/6 Our new 2025 Annual Update is available to read here
• 5/6 Patients diagnosed with Generalised Pustular Psoriasis are eligible on Spevigo (spesolimab) or conventional treatment
• 6/6 Reminder that we currently recruit for patients on Sotyktu (deucravacitinib)

Find out more on our website.